Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

1.3K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.3K
Bias01:22

Bias

7.2K
Bias refers to any tendency that prevents a question from being considered unprejudiced. In research, bias occurs when one outcome or answer is selected or encouraged over others in sampling or testing. Bias can occur during any research phase, including study design, data collection, analysis, and publication.
In statistics, a sampling bias is created when a sample is collected from a population, and some members of the population are not as likely to be chosen as others (remember, each member...
7.2K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

304
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
304
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

229
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
229
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

195
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
195
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Likelihood ratios of quantitative diagnostic test results.

Scandinavian journal of clinical and laboratory investigation·2026
Same author

Interpreting two test results of one analyte from the same individual using bivariate reference values.

Scandinavian journal of clinical and laboratory investigation·2026
Same author

Divide or subtract: transferrin saturation versus unbound iron binding capacity (UIBC).

Scandinavian journal of clinical and laboratory investigation·2026
Same author

Sample stability of forty-two analytes in plasma or serum pools after one to four repeated -80 °C freeze-thaw cycles.

Scandinavian journal of clinical and laboratory investigation·2025
Same author

Combining the calibrator uncertainty and the long-term measurement uncertainty? A comment to the ISO/TS 20914 guideline.

Clinical chemistry and laboratory medicine·2025
Same author

Testing MMA<sub>100</sub> - the eGFR-adjusted concentration of methylmalonic acid in plasma.

Scandinavian journal of clinical and laboratory investigation·2025

Related Experiment Video

Updated: Jan 19, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.5K

Allowable bias derived from the NOBIDA reference values.

Arne Åsberg1, Ingrid Hov Odsæter1,2

  • 1Department of Clinical Chemistry, Trondheim University Hospital , Trondheim , Norway.

Scandinavian Journal of Clinical and Laboratory Investigation
|September 26, 2019
PubMed
Summary
This summary is machine-generated.

Allowable bias figures are crucial for quality control and reference value validation. Non-parametric estimation using large datasets suggests a potentially larger allowable bias than previously assumed.

Keywords:
Allowable biasbiological variationbootstrapconfidence intervalsreference values

More Related Videos

Precise, High-throughput Analysis of Bacterial Growth
09:00

Precise, High-throughput Analysis of Bacterial Growth

Published on: September 19, 2017

24.8K
Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis
07:17

Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis

Published on: August 17, 2022

3.2K

Related Experiment Videos

Last Updated: Jan 19, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.5K
Precise, High-throughput Analysis of Bacterial Growth
09:00

Precise, High-throughput Analysis of Bacterial Growth

Published on: September 19, 2017

24.8K
Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis
07:17

Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis

Published on: August 17, 2022

3.2K

Area of Science:

  • Clinical Chemistry
  • Biostatistics
  • Laboratory Medicine

Background:

  • Allowable bias figures guide quality control, reference value assessment, and material stability.
  • Traditional allowable bias is often defined parametrically (0.25 * total biological standard deviation), based on limited sample sizes.
  • Published reference values frequently originate from populations smaller than the typical 120 individuals used in parametric calculations.

Purpose of the Study:

  • To non-parametrically estimate allowable bias using large-scale reference interval data.
  • To compare non-parametric estimation methods with traditional parametric approaches.
  • To evaluate the implications of non-parametric reference limit estimation on allowable bias figures.

Main Methods:

  • Non-parametric estimation of allowable bias using percentile differences from the Nordic reference interval project biobank and database (NOBIDA).
  • Estimation of allowable bias via resampling 120 reference values from NOBIDA datasets to derive non-parametric reference limits.
  • Comparison of allowable bias figures derived from percentile differences versus resampling methods.

Main Results:

  • Non-parametric estimation using percentile differences yielded allowable bias figures comparable to traditional parametric estimates.
  • Resampling methods to estimate non-parametric reference limits resulted in significantly larger allowable bias figures.
  • The findings indicate that non-parametric reference limit estimation implies a greater allowable bias than the conventional 0.25 * biological standard deviation.

Conclusions:

  • Non-parametric estimation of allowable bias from large datasets provides a more robust assessment.
  • Current methods for estimating reference limits non-parametrically may necessitate adjustments to allowable bias specifications.
  • The clinical utility of meeting these revised bias specifications for ensuring measurement quality remains to be determined.